Actuate Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$20.5MTTM through 30 Jun 2026
Free Cash Flow -$19.8MTTM through 30 Jun 2026
Margins
| Current |
|---|
Balance Sheet Health
Debt / Equity0.00x
Current Ratio1.81x
Net Debt-$8.1Mnet cash position
Cash & Equivalents$4.4M
Quality Metrics
Altman Z-Score-54.66
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
Diluted EPS-$0.87TTMFY2025: $-1.06
Dividend
No dividend
Capital Allocation
R&D Spend$8.9M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Drug Development | $0 | View detailsActuate continues to focus on clinical development of elraglusib, including planning for Phase 3 trials in metastatic pancreatic cancer and pediatric neuroblastoma studies. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.